The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SRRK | -1.81% | -26.15% | -5.88% | +97% |
| S&P | +18.37% | +110.18% | +16.02% | +152% |
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects.
A pundit at an influential U.S. bank is quite bullish on the company's future.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.42M | 16.3% |
| Market Cap | $3.36B | 406.2% |
| Market Cap / Employee | $17.16M | 0.0% |
| Employees | 196 | 30.7% |
| Net Income | -$110.03M | -88.1% |
| EBITDA | -$111.69M | -89.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $152.93M | 63.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $56.32M | -6.5% |
| Short Term Debt | $5.21M | -33.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -111.37% | -31.7% |
| Return On Invested Capital | -48.29% | -2.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$77.16M | -56.8% |
| Operating Free Cash Flow | -$76.94M | -56.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.10 | 43.70 | 8.18 | 10.76 | 196.04% |
| Price to Tangible Book Value | 8.10 | 43.70 | 8.18 | 10.76 | 196.04% |
| Enterprise Value to EBITDA | -10.96 | -53.40 | -42.95 | -33.65 | 190.26% |
| Return on Equity | -183.1% | -82.9% | -106.7% | -172.1% | 41.87% |
| Total Debt | $66.61M | $65.13M | $63.14M | $61.53M | -9.57% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
